Giant Cell Arteritis
https://doi.org/10.23934/2223-9022-2024-13-4-641-649
Abstract
Giant cell arteritis is a disease characterized by granulomatous inflammation of large and medium-sized arteries. The aorta and its large branches are most susceptible to pathological changes in this arteritis. The course of giant cell arteritis is often complicated by ischemia in the blood supply basin of the artery involved in the pathological process. Variants of such complications may be ischemic optic neuropathy and retinopathy, limb ischemia, and acute cerebrovascular accident. This review presents current data on the etiology and pathogenesis of giant cell arteritis, prevalence, sensitivity, and specificity of clinical and instrumental signs of this disease, as well as practical recommendations for various treatment methods during exacerbation and remission.
Keywords
giant cell arteritis,
Horton’s disease,
temporal arteritis,
non-atherosclerotic vasculopathy,
vasculitis
Supporting agencies: The study had no sponsorship
About the Authors
E. V. Shevchenko
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Evgeny V. Shevchenko - Candidate of Medical Sciences, Head of the Neurological Department for Patients with Acute Cerebrovascular Accidents, Senior Researcher of the Scientific Department of Emergency Neurology and Rehabilitation Treatment, N.V. Sklifosovsky RIEM.
Bolshaya Sukharevskaya Sq. 3, Moscow
A. M. Izmailova
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Aza M. Izmailova - Junior Researcher, Department of Emergency Neurology and Rehabilitation, N.V. Sklifosovsky RIEM.
Bolshaya Sukharevskaya Sq. 3, Moscow
E. A. Kovaleva
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Ella A. Kovaleva - Candidate of Medical Sciences, Senior Lecturer, Educational Department, Senior Researcher, Scientific Department of Emergency Neurology and Rehabilitation Treatment, N.V. Sklifosovsky RIEM.
Bolshaya Sukharevskaya Sq. 3, Moscow
G. R. Ramazanov
N.V. Sklifosovsky Research Institute for Emergency Medicine
Russian Federation
Russian Federation
Ganipa R. Ramazanov - Candidate of Medical Sciences, Deputy Director, Head of the Regional Vascular Center, N.V. Sklifosovsky RIEM, Head of the Scientific Department of Emergency Neurology and Rehabilitation Treatment
Bolshaya Sukharevskaya Sq. 3, Moscow
References
1. Visvanathan S, Rahman MU, Hoffman GS, Xu S, García-Martínez A, Segarra M, et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis--a prospective longitudinal study. Rheumatology (Oxford). 2011;50(11):2061–2070. PMID: 21873264 https://doi.org/10.1093/rheumatology/ker163
2. de Boysson H, Daumas A, Vautier M, Parienti JJ, Liozon E, Lambert M, et al. Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients. Autoimmun Rev. 2018;17(4):391–398. PMID: 29427822 https://doi.org/10.1016/j.autrev.2017.11.029
3. Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol. 1972;27(5):378–391. PMID: 5078894 https://doi.org/10.1001/archneur.1972.00490170010003
4. Cid MC, Hernández-Rodríguez J, Esteban MJ, Cebrián M, Gho YS, Font C, et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation. 2002;106(13):1664–1671. PMID: 12270860 https://doi.org/10.1161/01.cir.0000030185.67510.c0
5. Pfadenhauer K, Esser M, Weber H, Wölfle KD. Vertebrobasiläre Ischämie als Komplikation der Arteriitis temporalis. Ergebnisse einer prospektiven klinischen und ultrasonographischen Untersuchung [Vertebrobasilar ischemia as a complication of temporal arteritis. Results of a prospective, clinical, ultrasonographic study]. Nervenarzt. 2005;76(8):954–959. PMID: 15580463 https://doi.org/10.1007/s00115-004-1853-x German.
6. Boes CJ. Bayard Horton’s clinicopathological description of giant cell (temporal) arteritis. Cephalalgia. 2007;27(1):68–75. PMID: 17212686 https://doi.org/10.1111/j.1468-2982.2007.01238.x
7. Emmerich J, Fiessinger JN. Epidémiologie et facteurs étiologiques des artérites à cellules géantes (maladie de Horton et maladie de Takayasu) [Epidemiology and etiological factors in giant cell arteritis (Horton’s disease and Takayasu’s disease)]. Ann Med Interne (Paris). 1998;149(7):425–432. PMID: 9921396 French.
8. Duhaut P. Nosologie et épidémiologie de la maladie de Horton et de la pseudopolyarthrite rhizomélique [Nosology and epidemiology of Horton’s disease and polymyalgia rheumatica]. Rev Prat. 1999;49(6):588–592. PMID: 10218392 French.
9. Le Page L, Duhaut P, Seydoux D, Bosshard S, Ecochard R, Abbas F, et al. Incidence des accidents cardiovasculaires au cours de la maladie de Horton: résultats préliminaires de l’étude prospective en double cohorte GRACG [Incidence of cardiovascular events in giant cell arteritis: preliminary results of a prospective double cohort study (GRACG)]. Rev Med Interne. 2006;27(2):98–105. PMID: 16310894 https://doi.org/10.1016/j.revmed.2005.10.009 French.
10. Weyand CM, Goronzy JJ. Immune mechanisms in medium and largevessel vasculitis. Nat Rev Rheumatol. (2013) 9:731–740. PMID: 24189842 https://doi.org/10.1038/nrrheum.2013.161
11. Stamatis P, Turesson C, Michailidou D, Mohammad AJ. Pathogenesis of giant cell arteritis with focus on cellular populations. Front Med (Lausanne). 2022;9:1058600. PMID: 36465919 https://doi.org/10.3389/fmed.2022.1058600 eCollection 2022.
12. Chen L, Deng H, Cui H, Fang J, Zuo Z, Deng J, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2017;9(6):7204–7218. PMID: 29467962 https://doi.org/10.18632/oncotarget.23208
13. Koster MJ, Warrington KJ. Giant cell arteritis: pathogenic mechanisms and new potential therapeutic targets. BMC Rheumatol. 2017;1:2. PMID: 30886946 https://doi.org/10.1186/s41927-017-0004-5
14. Deng J, Ma-Krupa W, Gewirtz AT, Younge BR, Goronzy JJ, Weyand CM. Toll-like receptors 4 and 5 induce distinct types of vasculitis. Circ Res. 2009;104(4):488–495. PMID: 19150884 https://doi.org/10.1161/CIRCRESAHA.108.185777
15. Weyand CM, Liao YJ, Goronzy JJ. The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuro-Ophthalmol. 2012;32(3):259–265. PMID: 22914691 https://doi.org/10.1097/ WNO.0b013e318268aa9b
16. Cavazza A, Muratore F, Boiardi L, Restuccia G, Pipitone N, Pazzola G, et al. Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations. Am J Surg Pathol. 2014;38(10):1360–1370. PMID: 25216320 https://doi.org/10.1097/PAS.0000000000000244
17. Brodbeck WG, Anderson JM. Giant cell formation and function. Curr Opin Hematol. 2009;16(1):53–57. PMID: 19057205 https://doi.org/10.1097/MOH.0b013e32831ac52e
18. Maddur MS, Miossec P, Kaveri SV, Bayry J. Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol. 2012;181(1):8–18. PMID: 22640807 https://doi.org/10.1016/j.ajpath.2012.03.044
19. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM, Deng J, et al. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation. 2010;121(7):906–195. PMID: 20142449 https://doi.org/10.1161/CIRCU LATIONAHA.109.872903
20. Wadström K, Jacobsson LTH, Mohammad AJ, Warrington KJ, Matteson EL, Jakobsson ME, et al. Analyses of plasma inflammatory proteins reveal biomarkers predictive of subsequent development of giant cell arteritis: a prospective study. Rheumatology (Oxford). 2023;62(6):2304–2311. PMID: 36255228 https://doi.org/10.1093/rheumatology/keac581
21. Ponte C, Martins-Martinho J, Luqmani RA. Diagnosis of giant cell arteritis. Rheumatology (Oxford). 2020;59(Suppl 3):iii5–iii16. PMID: 32348512 https://doi.org/10.1093/rheumatology/kez553
22. van der Geest KSM, Sandovici M, Brouwer E, Mackie SL. Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis. JAMA Intern Med. 2020;180(10):1295–1304. PMID: 32804186 https://doi.org/10.1001/jamainternmed.2020.3050
23. Ward TN, Levin M. Headache in giant cell arteritis and other arteritides. Neurol Sci. 2005;26(Suppl 2):S134–S137. PMID: 15926011 https://doi.org/10.1007/s10072-005-0426-5
24. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122– 1128. PMID: 2202311 https://doi.org/10.1002/art.1780330810
25. Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis [published correction appears in Ann Rheum Dis. 2023 Feb;82(2):e52]. Ann Rheum Dis. 2022;81(12):1647–1653. PMID: 36351706 https://doi.org/10.1136/ard-2022-223480
26. Thomas DC, Thomas P, Pillai DP, Joseph D, Lingaiah U, Mathai BC, et al. Giant Cell Arteritis: A Case-Based Narrative Review of the Literature. Curr Pain Headache Rep. 2022;26(10):725–740. PMID: 36057073 https://doi.org/10.1007/s11916-022-01075-1
27. Simon S, Ninan J, Hissaria P. Diagnosis and management of giant cell arteritis: major review. Clin Exp Ophthalmol. 2021;49(2):169–185. PMID: 33426764 https://doi.org/10.1111/ceo.13897
28. Hayreh SS. Giant cell arteritis: Its ophthalmic manifestations. Indian J Ophthalmol. 2021;69(2):227–235. PMID: 33463564 https://doi.org/10.4103/ijo.IJO_1681_20
29. Héron E, Sedira N, Dahia O, Jamart C. Ocular Complications of Giant Cell Arteritis: An Acute Therapeutic Emergency. J Clin Med. 2022;11(7):1997. PMID: 35407604 https://doi.org/10.3390/jcm11071997
30. Gonzalez-Gay MA, Castañeda S, Llorca J. Giant Cell Arteritis: Visual Loss Is Our Major Concern. J Rheumatol. 2016;43(8):1458–1461. PMID: 27481989 https://doi.org/10.3899/jrheum.160466
31. Nordborg C, Nordborg E, Petursdottir V. Giant cell arteritis. Epidemiology, etiology and pathogenesis. Apmis. 2000;108(11):713–724. PMID: 11211963 https://doi.org/10.1034/j.1600-0463.2000.d01-19.x
32. Czihal M, Tschaidse J, Bernau C, Lottspeich C, Köhler A, Dechant C, et al. Ocular ischaemic complications in giant cell arteritis: CHADS2-score predicts risk of permanent visual impairment. Clin Exp Rheumatol. 2019;37(Suppl 117):61–64. PMID: 31162028
33. Dejaco C, Brouwer E, Mason JC, Buttgereit F, Matteson EL, Dasgupta B. Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities. Nat Rev Rheumatol. 2017;13(10):578–592. PMID: 2890586 https://doi.org/10.1038/nrrheum.2017.142
34. Ungprasert P, Wijarnpreecha K, Koster MJ, Thongprayoon C, Warrington KJ. Cerebrovascular accident in patients with giant cell arteritis: A systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2016;46(3):361–366. PMID: 27546492 https://doi.org/10.1016/j.semarthrit.2016.07.005
35. Samson M, Jacquin A, Audia S, Daubail B, Devilliers H, Petrella T, et al. Stroke associated with giant cell arteritis: a population-based study. J Neurol Neurosurg Psychiatry. 2015;86(2):216–221. PMID: 24780954 https://doi.org/10.1136/jnnp-2014-307614
36. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, PegoReigosa R, Lopez-Diaz MJ, Vazquez-Triñanes MC, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimor). 2009;88(4):227–235. PMID: 19593228 https://doi.org/10.1097/MD.0b013e3181af4518
37. Caselli RJ, Daube JR, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology. 1988;38(3):352–359. PMID: 3347337 https://doi.org/10.1212/wnl.38.3.352
38. Assie C, Janvresse A, Plissonnier D, Levesque H, Marie I. Long-term follow-up of upper and lower extremity vasculitis related to giant cell arteritis: a series of 36 patients. Medicine (Baltimore). 2011;90(1):40–51. PMID: 21200185 https://doi.org/10.1097/MD.0b013e318206af16
39. Assie C, Marie I. Atteintes artérielles des membres supérieurs et inférieurs au cours de la maladie de Horton [Giant cell arteritis-related upper/lower limb vasculitis]. Presse Med. 2011;40(2):151–161. PMID: 21239139 https://doi.org/10.1016/j.lpm.2010.11.005 French.
40. Prieto-Peña D, Castañeda S, Atienza-Mateo B, Blanco R, GonzálezGay MÁ. A Review of the Dermatological Complications of Giant Cell Arteritis. Clin Cosmet Investig Dermatol. 2021;14:303–312. PMID: 33790612 https://doi.org/10.2147/CCID.S284795 eCollection 2021.
41. Kaymakci MS, Boire NA, Bois MC, Elfishawi MM, Langenfeld HE, Hanson AC, et al. Persistent aortic inflammation in patients with giant cell arteritis. Autoimmun Rev. 2023;22(9):103411. PMID: 37597603 https://doi.org/10.1016/j.autrev.2023.103411
42. Evans JM, O’Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122(7):502–507. PMID: 7872584 https://doi.org/10.7326/0003-4819-122-7-199504010-00004
43. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48(12):3522–3531. PMID: 14674004 https://doi.org/10.1002/art.11353
44. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122– 1128. PMID: 2202311 https://doi.org/10.1002/art.1780330810
45. Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: Revisiting the concept of the disease. Rheumatology (Oxford). 2017;56(4):506–515. PMID: 27481272 https://doi.org/10.1093/rheumatology/kew273
46. Murchison AP, Gilbert ME, Bilyk JR, Eagle RC, Pueyo V, Sergott RC, et al. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol. 2012;154(4):722–729. PMID: 22809782 https://doi.org/10.1016/j.ajo.2012.03.045
47. Filatova EE, Bulanov NM, Borodin OO, Meshkov AD, Smitienko IO, Chachilo EV, et al. Comparison of classification criteria for giant cell arteritis. Clin Pharmacol Ther. 2023;32(3):44–49 (In Russ.). https://doi.org/10.32756/0869-5490-2023-3-44-49
48. Rubenstein E, Maldini C, Gonzalez-Chiappe S, Chevret S, Mahr A. Sensitivity of temporal artery biopsy in the diagnosis of giant cell arteritis: a systematic literature review and meta-analysis. Rheumatology (Oxford). 2020;59(5):1011–1020. PMID: 31529073 https://doi.org/10.1093/rheumatology/kez385
49. Lie JT. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum. 1990;33(8):1074–1087. PMID: 1975173 https://doi.org/10.1002/art.1780330804
50. Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP. Meta-analysis: test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005;142(5):359–369. PMID: 15738455 https://doi.org/10.7326/0003-4819-142-5-200503010-00011
51. Moreel L, Betrains A, Doumen M, Molenberghs G, Vanderschueren S, Blockmans D. Diagnostic yield of combined cranial and large vessel PET/CT, ultrasound and MRI in giant cell arteritis: A systematic review and meta-analysis. Autoimmun Rev. 2023;22(7):103355. PMID: 37146926 https://doi.org/10.1016/j.autrev.2023.103355
52. Pérez López J, Solans Laqué R, Bosch Gil JA, Molina Cateriano C, Huguet Redecilla P, Vilardell Tarrés M. Colour-duplex ultrasonography of the temporal and ophthalmic arteries in the diagnosis and follow-up of giant cell arteritis. Clin Exp Rheumatol. 2009;27(1 Suppl 52):S77–S82. PMID: 19646351
53. Nielsen BD, Gormsen LC. 18F-Fluorodeoxyglucose PET/Computed Tomography in the Diagnosis and Monitoring of Giant Cell Arteritis. PET Clin. 2020;15(2):135–145. PMID: 32145884 https://doi.org/10.1016/j.cpet.2019.11.007
54. Conway R, Smyth AE, Kavanagh RG, O’Donohoe RL, Purcell Y, Heffernan EJ, et al. Diagnostic Utility of Computed Tomographic Angiography in Giant-Cell Arteritis. Stroke. 2018;49(9):2233–2236. PMID: 30354972 https://doi.org/10.1161/STROKEAHA.118.021995
55. Bosch P, Bond M, Dejaco C, Ponte C, Mackie SL, Falzon L, et al. Imaging in diagnosis, monitoring and outcome prediction of large vessel vasculitis: a systematic literature review and meta-analysis informing the 2023 update of the EULAR recommendations. RMD Open. 2023;9(3): e003379. PMID: 37620113 https://doi.org/10.1136/rmdopen-2023003379
56. Bley TA, Uhl M, Markl M, Frydrychowicz A, Langer M. Magnetresonanztomografie der Arteriitis temporalis Horton [MRI in giant cell (temporal) arteritis]. Rofo. 2007;179(7):703–711. PMID: 17657703 https://doi.org/10.1055/s-2007-963123 German.
57. Reinhard M, Schmidt WA, Hetzel A, Bley TA. Bildgebung der Riesenzellarteriitis. Sonographie und MRT [Imaging techniques for giant cell arteritis. Ultrasound and MRI]. Z Rheumatol. 2009;68(2):108–116. PMID: 19153753 https://doi.org/10.1007/s00393-008-0375-5 German.
58. Remond P, Attyé A, Lecler A, Lamalle L, Boudiaf N, Aptel F, et al. The Central Bright Spot Sign: A Potential New MR Imaging Sign for the Early Diagnosis of Anterior Ischemic Optic Neuropathy due to Giant Cell Arteritis. AJNR Am J Neuroradiol. 2017;38(7):1411–1415. PMID: 28495949 https://doi.org/10.3174/ajnr.A5205
59. Dua AB, Husainat NM, Kalot MA, Byram K, Springer JM, James KE, et al. Giant Cell Arteritis: A Systematic Review and Meta-Analysis of Test Accuracy and Benefits and Harms of Common Treatments. ACR Open Rheumatol. 2021;3(7):429–441. PMID: 33811481 https://doi.org/10.1002/acr2.11226
60. Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30. PMID: 31270110 https://doi.org/10.1136/annrheumdis-2019-215672
61. Ughi N, Padoan R, Crotti C, Sciascia S, Carrara G, Zanetti A, et al. The Italian Society of Rheumatology clinical practice guidelines for the management of large vessel vasculitis. Reumatismo. 2022;73(4). PMID: 35130681 https://doi.org/10.4081/reumatismo.2021.1470
62. Macaluso F, Marvisi C, Castrignanò P, Pipitone N, Salvarani C. Comparing treatment options for large vessel vasculitis. Expert Rev Clin Immunol. 2022;18(8):793–805. PMID: 35714219 https://doi.org/10.1080/1744666X.2022.2092098
Review
For citations:
Shevchenko E.V., Izmailova A.M., Kovaleva E.A., Ramazanov G.R. Giant Cell Arteritis. Russian Sklifosovsky Journal "Emergency Medical Care". 2024;13(4):641-649. (In Russ.) https://doi.org/10.23934/2223-9022-2024-13-4-641-649
Views:
198
Email this article 